Not Yet RecruitingNot Applicable

Oteseconazole in the Treatment of Adults With Vulvovaginal Candidiasis（VVC）

3,000 participantsStarted 2025-08-10

Plain-language summary

Oteseconazole is a novel, oral, highly selective inhibitor of fungal CYP51. Oteseconazole showed statistically significant and clinically meaningful treatment of severe VVC and was generally tolerated. The trial is a national multi-center, non-interventional observational real-world study, aiming to evaluate the effecacy and safety of oteseconazole in the treatment of patients with VVC. This study will include patients with severe vulvovaginal candidiasis (SVVC) . It is divided into prospective and retrospective parts.

Who can participate

Age range18 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * ≥ 18 years old, female; vulvovaginal signs and symptoms (VSS) score ≥7; Plan to use oteseconazole monotherapy or combination therapy Exclusion Criteria: * Evidence has shown that the patient whohas been pregnant or lactating; Patients who are participating in or planning to participate in other interventional clinical studies; Other situations determined by the researcher as unsuitable for inclusion in the study

What they're measuring

The proportion of subjects achieving clinical cure at 6-month,

Timeframe: 6-month after the end of treatment

Trial details

NCT IDNCT07044947

SponsorBeijing Tsinghua Chang Gung Hospital

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2027-08-10

View on ClinicalTrials.gov More Vulvovaginal Candidiasis trials